Interesting study that you posted CitySlicker. A big limitation is that it does not appear that the study focused on any one particular type of glucose-lowering intervention therapy. Metformin, insulin, SGLT2-inhibitors, GLP-1R agonists, DPP4 inhibitors, insulin sensitizing TZDs, sulfonylurea secretagogues, etc......all have different mechanisms of action and tissue distribution. It would be much stronger to see cognitive function data from glucose-lowering and/or CVOT trials using these individual therapies instead of a broad association study consisting of patients on many different therapies. Just my 2 cents.

As for apabetalone and glucose control.......glucose metabolism used to be one of the six pieces of the pie in the apabetalone mechanism diagram. However, they recently replaced this with acute phase response. Although Phase 2 data (see this post) suggested that apabetalone may elicit a glucose-lowering effect compared to placebo, this was not observed in BETonMACE (see slide 54).

BDAZ